CN101632676A - 治疗寄生原虫感染所致疾病的三嗪酮类化合物 - Google Patents

治疗寄生原虫感染所致疾病的三嗪酮类化合物 Download PDF

Info

Publication number: CN101632676A
Authority: CN; China
Prior art keywords: cell; toltrazuril; neospora; formula; disease
Prior art date: 1999-12-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN200910142693A

Other languages

English (en)

Chinese (zh)

Inventor

G·格雷夫

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Bayer AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-03

Filing date

2000-11-21

Publication date

2010-01-27

2000-11-21 Application filed by Bayer AG filed Critical Bayer AG

2010-01-27 Publication of CN101632676A publication Critical patent/CN101632676A/zh

Status Pending legal-status Critical Current

Links

230000003071 parasitic effect Effects 0.000 title claims abstract description 19
QMNWYGTWTXOQTP-UHFFFAOYSA-N 1h-triazin-6-one Chemical class O=C1C=CN=NN1 QMNWYGTWTXOQTP-UHFFFAOYSA-N 0.000 title claims description 17
201000010099 disease Diseases 0.000 title description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 25
206010061217 Infestation Diseases 0.000 title description 3
241001465754 Metazoa Species 0.000 claims abstract description 25
241001147660 Neospora Species 0.000 claims description 55
OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 claims description 36
229960000898 toltrazuril Drugs 0.000 claims description 34
150000001875 compounds Chemical class 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 5
229960005486 vaccine Drugs 0.000 claims description 5
239000013066 combination product Substances 0.000 claims 1
229940127555 combination product Drugs 0.000 claims 1
FKBYRZCVXYSLEL-UHFFFAOYSA-N 1h-triazine-4,5,6-trione Chemical class O=C1NN=NC(=O)C1=O FKBYRZCVXYSLEL-UHFFFAOYSA-N 0.000 abstract description 3
BFGQTWYXWNCTSX-UHFFFAOYSA-N triazine-4,5-dione Chemical class O=C1C=NN=NC1=O BFGQTWYXWNCTSX-UHFFFAOYSA-N 0.000 abstract description 3
241000282472 Canis lupus familiaris Species 0.000 description 47
210000004027 cell Anatomy 0.000 description 36
210000000059 tachyzoite Anatomy 0.000 description 26
241000699670 Mus sp. Species 0.000 description 24
208000015181 infectious disease Diseases 0.000 description 24
238000000034 method Methods 0.000 description 23
210000001519 tissue Anatomy 0.000 description 23
239000003814 drug Substances 0.000 description 21
244000045947 parasite Species 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 18
-1 Carboxylic acid isocyanate Chemical class 0.000 description 17
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
239000001963 growth medium Substances 0.000 description 15
208000024891 symptom Diseases 0.000 description 15
238000011282 treatment Methods 0.000 description 15
241000283690 Bos taurus Species 0.000 description 14
239000001257 hydrogen Substances 0.000 description 14
229910052739 hydrogen Inorganic materials 0.000 description 14
230000034994 death Effects 0.000 description 13
230000000694 effects Effects 0.000 description 13
241000699666 Mus <mouse, genus> Species 0.000 description 12
238000004113 cell culture Methods 0.000 description 12
239000013553 cell monolayer Substances 0.000 description 12
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
238000012360 testing method Methods 0.000 description 12
229910052736 halogen Inorganic materials 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
230000002490 cerebral effect Effects 0.000 description 10
201000002491 encephalomyelitis Diseases 0.000 description 10
150000002367 halogens Chemical class 0.000 description 10
239000000243 solution Substances 0.000 description 10
239000000460 chlorine Substances 0.000 description 9
229910052801 chlorine Inorganic materials 0.000 description 9
150000002431 hydrogen Chemical class 0.000 description 9
238000003752 polymerase chain reaction Methods 0.000 description 9
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
229940079593 drug Drugs 0.000 description 8
229910052731 fluorine Inorganic materials 0.000 description 8
239000011737 fluorine Substances 0.000 description 8
125000005843 halogen group Chemical group 0.000 description 8
241000283073 Equus caballus Species 0.000 description 7
241000282326 Felis catus Species 0.000 description 7
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 7
241000224003 Sarcocystis Species 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
229910052799 carbon Inorganic materials 0.000 description 7
125000004432 carbon atom Chemical group C* 0.000 description 7
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
208000030852 Parasitic disease Diseases 0.000 description 6
241001494479 Pecora Species 0.000 description 6
229930182555 Penicillin Natural products 0.000 description 6
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
241000223996 Toxoplasma Species 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 6
150000001412 amines Chemical class 0.000 description 6
230000004888 barrier function Effects 0.000 description 6
239000002585 base Substances 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
239000010410 layer Substances 0.000 description 6
229940049954 penicillin Drugs 0.000 description 6
229960005322 streptomycin Drugs 0.000 description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
206010000234 Abortion spontaneous Diseases 0.000 description 5
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
208000003495 Coccidiosis Diseases 0.000 description 5
206010023076 Isosporiasis Diseases 0.000 description 5
208000012902 Nervous system disease Diseases 0.000 description 5
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
241000223997 Toxoplasma gondii Species 0.000 description 5
125000003342 alkenyl group Chemical group 0.000 description 5
125000003545 alkoxy group Chemical group 0.000 description 5
125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
125000004414 alkyl thio group Chemical group 0.000 description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
229910052794 bromium Inorganic materials 0.000 description 5
239000006285 cell suspension Substances 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
239000012948 isocyanate Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
208000015994 miscarriage Diseases 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
230000003169 placental effect Effects 0.000 description 5
208000000995 spontaneous abortion Diseases 0.000 description 5
210000003501 vero cell Anatomy 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
229930182816 L-glutamine Natural products 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
206010000210 abortion Diseases 0.000 description 4
231100000176 abortion Toxicity 0.000 description 4
125000000304 alkynyl group Chemical group 0.000 description 4
125000004104 aryloxy group Chemical group 0.000 description 4
230000001605 fetal effect Effects 0.000 description 4
238000007710 freezing Methods 0.000 description 4
230000008014 freezing Effects 0.000 description 4
125000004440 haloalkylsulfinyl group Chemical group 0.000 description 4
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
239000013641 positive control Substances 0.000 description 4
230000002265 prevention Effects 0.000 description 4
238000012545 processing Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
ZSZFUDFOPOMEET-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl ZSZFUDFOPOMEET-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
206010003591 Ataxia Diseases 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
206010033799 Paralysis Diseases 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
150000001342 alkaline earth metals Chemical class 0.000 description 3
230000008499 blood brain barrier function Effects 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
244000309466 calf Species 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
229960000248 diclazuril Drugs 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
210000003754 fetus Anatomy 0.000 description 3
239000007789 gas Substances 0.000 description 3
238000010166 immunofluorescence Methods 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
239000002917 insecticide Substances 0.000 description 3
150000002513 isocyanates Chemical class 0.000 description 3
238000000386 microscopy Methods 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
239000007800 oxidant agent Substances 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000003449 preventive effect Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
210000000278 spinal cord Anatomy 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
150000003672 ureas Chemical class 0.000 description 3
MHVJUTLRTHDAOG-UHFFFAOYSA-N (4-hydroxyphenyl)urea Chemical compound NC(=O)NC1=CC=C(O)C=C1 MHVJUTLRTHDAOG-UHFFFAOYSA-N 0.000 description 2
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
208000032170 Congenital Abnormalities Diseases 0.000 description 2
206010011732 Cyst Diseases 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
241000283086 Equidae Species 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108091023242 Internal transcribed spacer Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001597008 Nomeidae Species 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
206010037779 Radiculopathy Diseases 0.000 description 2
208000019802 Sexually transmitted disease Diseases 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
229920006329 Styropor Polymers 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
201000005485 Toxoplasmosis Diseases 0.000 description 2
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
210000002718 aborted fetus Anatomy 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000003513 alkali Substances 0.000 description 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
235000013877 carbamide Nutrition 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
208000031513 cyst Diseases 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
238000004043 dyeing Methods 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
210000003936 merozoite Anatomy 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000003387 muscular Effects 0.000 description 2
210000000107 myocyte Anatomy 0.000 description 2
210000004493 neutrocyte Anatomy 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
231100000915 pathological change Toxicity 0.000 description 2
230000036285 pathological change Effects 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
206010061928 radiculitis Diseases 0.000 description 2
239000002994 raw material Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
229960004306 sulfadiazine Drugs 0.000 description 2
229940124530 sulfonamide Drugs 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000000725 suspension Substances 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
238000010257 thawing Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QICKOOCQSYZYQB-UHFFFAOYSA-N (4-hydroxyphenyl)thiourea Chemical compound NC(=S)NC1=CC=C(O)C=C1 QICKOOCQSYZYQB-UHFFFAOYSA-N 0.000 description 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
150000000182 1,3,5-triazines Chemical class 0.000 description 1
OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
ZKITXAAKDFPASL-UHFFFAOYSA-N 1-isothiocyanato-4-phenoxybenzene Chemical compound C1=CC(N=C=S)=CC=C1OC1=CC=CC=C1 ZKITXAAKDFPASL-UHFFFAOYSA-N 0.000 description 1
QDFXRVAOBHEBGJ-UHFFFAOYSA-N 3-(cyclononen-1-yl)-4,5,6,7,8,9-hexahydro-1h-diazonine Chemical compound C1CCCCCCC=C1C1=NNCCCCCC1 QDFXRVAOBHEBGJ-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
241000283707 Capra Species 0.000 description 1
CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000867610 Chlorocebus pygerythrus Species 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
238000007399 DNA isolation Methods 0.000 description 1
206010061619 Deformity Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000222065 Lycoperdon Species 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
208000003926 Myelitis Diseases 0.000 description 1
ZBCXEVHCQFXVNC-UHFFFAOYSA-N N.[Ce+4] Chemical compound N.[Ce+4] ZBCXEVHCQFXVNC-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
241001147662 Neospora caninum Species 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108010019160 Pancreatin Proteins 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
241000768494 Polymorphum Species 0.000 description 1
208000010362 Protozoan Infections Diseases 0.000 description 1
206010056658 Pseudocyst Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
230000018199 S phase Effects 0.000 description 1
241000146987 Sarcocystis neurona Species 0.000 description 1
241000522620 Scorpio Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
241000282485 Vulpes vulpes Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910000272 alkali metal oxide Inorganic materials 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
150000001356 alkyl thiols Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
244000144987 brood Species 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
229960002227 clindamycin Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
208000012839 conversion disease Diseases 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
125000004472 dialkylaminosulfonyl group Chemical group 0.000 description 1
229940117389 dichlorobenzene Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
125000000232 haloalkynyl group Chemical group 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
229940027941 immunoglobulin g Drugs 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
231100000299 mutagenicity Toxicity 0.000 description 1
230000007886 mutagenicity Effects 0.000 description 1
VBBUFMFZDHLELS-UHFFFAOYSA-N n-(oxomethylidene)carbamoyl chloride Chemical class ClC(=O)N=C=O VBBUFMFZDHLELS-UHFFFAOYSA-N 0.000 description 1
125000006606 n-butoxy group Chemical group 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
210000003360 nephrocyte Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
210000003889 oxyphil cell of parathyroid gland Anatomy 0.000 description 1
229940055695 pancreatin Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000003108 parasitologic effect Effects 0.000 description 1
210000004417 patella Anatomy 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
150000004965 peroxy acids Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
210000002706 plastid Anatomy 0.000 description 1
235000013824 polyphenols Nutrition 0.000 description 1
229960003508 ponazuril Drugs 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
239000002423 protozoacide Substances 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001563 schizont Anatomy 0.000 description 1
239000009490 scorpio Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
241000894007 species Species 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
229940118701 toxoplasma gondii Drugs 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
- A01N43/66—1,3,5-Triazines, not hydrogenated and not substituted at the ring nitrogen atoms
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
- A01N43/707—1,2,3- or 1,2,4-triazines; Hydrogenated 1,2,3- or 1,2,4-triazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Environmental Sciences (AREA)
Pest Control & Pesticides (AREA)
Plant Pathology (AREA)
Dentistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Agronomy & Crop Science (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CN200910142693A 1999-12-03 2000-11-21 治疗寄生原虫感染所致疾病的三嗪酮类化合物 Pending CN101632676A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19958388.9		1999-12-03
DE19958388A DE19958388A1 (de)	1999-12-03	1999-12-03	Triazinonverbindungen zur Behandlung von durch den Befall mit parasitischen Protozoen bedingten Krankheiten

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CN00816674A Division CN1407893A (zh)	1999-12-03	2000-11-21	治疗寄生原虫感染所致疾病的三嗪酮类化合物

Publications (1)

Publication Number	Publication Date
CN101632676A true CN101632676A (zh)	2010-01-27

Family

ID=7931344

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN200910142693A Pending CN101632676A (zh)	1999-12-03	2000-11-21	治疗寄生原虫感染所致疾病的三嗪酮类化合物
CN00816674A Pending CN1407893A (zh)	1999-12-03	2000-11-21	治疗寄生原虫感染所致疾病的三嗪酮类化合物

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN00816674A Pending CN1407893A (zh)	1999-12-03	2000-11-21	治疗寄生原虫感染所致疾病的三嗪酮类化合物

Country Status (16)

Country	Link
US (1)	US9399037B2 (de)
EP (1)	EP1246624B1 (de)
JP (1)	JP5031163B2 (de)
CN (2)	CN101632676A (de)
AT (1)	ATE298573T1 (de)
AU (1)	AU783437B2 (de)
BR (1)	BR0015996A (de)
CA (1)	CA2394188C (de)
DE (2)	DE19958388A1 (de)
DK (1)	DK1246624T3 (de)
ES (1)	ES2243323T3 (de)
HU (1)	HU226379B1 (de)
MX (1)	MXPA02005479A (de)
NZ (1)	NZ519327A (de)
WO (1)	WO2001039778A2 (de)
ZA (1)	ZA200203476B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102007025908A1 (de)	2007-06-01	2008-12-04	Bayer Healthcare Ag	Formulierungen enthaltend Triazinone und Eisen
MX2008009818A (es)	2008-07-31	2010-02-01	Avi Mex S A De C V Lab	Combinacion coccidicida para uso veterinario.
DE102009012423A1 (de)	2009-03-10	2010-09-16	Bayer Animal Health Gmbh	Zubereitung auf Ölbasis
DE102009038949A1 (de) *	2009-08-26	2011-03-03	Bayer Animal Health Gmbh	Neue Verwendung von heterocyclisch substituierten 1,2,4-Triazindionen
MA52415A (fr)	2018-02-26	2021-01-06	AlzeCure Pharma AB	Dérivés de triazine pour le traitement de maladies associées à des neurotrophines
GB201810668D0 (en)	2018-06-28	2018-08-15	Stiftelsen Alzecure	New compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4778887A (en)	1984-08-01	1988-10-18	Janssen Pharmaceutica N.V.	α-aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitriles
US4631278A (en)	1984-08-01	1986-12-23	Janssen Pharmaceutica N.V.	Anti-protozoal α-aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile derivatives, pharmaceutical compositions, and method of use therefor
DE3805660A1 (de)	1988-02-24	1989-09-07	Bayer Ag	Substituierte 1,2,4-triazindione, verfahren zu ihrer herstellung und ihre verwendung
DE3826058A1 (de)	1988-07-30	1990-02-08	Bayer Ag	Mittel gegen fischparasiten
US5196562A (en)	1988-10-08	1993-03-23	Bayer Aktiengesellschaft	Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
US4933341A (en)	1988-10-08	1990-06-12	Bayer Aktiengesellschaft	Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
EP0377903A3 (de)	1989-01-09	1991-07-17	Bayer Ag	Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
CN1044905A (zh)	1989-02-16	1990-08-29	赫彻斯特股份公司	鱼和昆虫寄生虫对抗剂
DE4030042A1 (de)	1990-05-17	1991-11-21	Bayer Ag	Verwendung von substituierten 1,2,4-triazindionen
US5256632A (en)	1990-05-30	1993-10-26	Bayer Aktiengesellschaft	Herbicidal sulphonylated carboxamides
DE19519821A1 (de) *	1995-05-31	1996-12-05	Bayer Ag	Mittel gegen parasitäre Protozoen
JP4056099B2 (ja) *	1996-05-09	2008-03-05	森永乳業株式会社	水生動物の寄生生物性疾患の予防および治療剤
ATE271122T1 (de)	1996-11-12	2004-07-15	Pfizer	Attenuierter lebender neospora impfstoff
BR9808114A (pt) *	1997-03-31	2000-03-08	David Granstrom	Formulação de ração para cavalos utilizável para tratar epm, processos para tratar pm em um cavalo que necessita deste tratamento, para prevenir infecção com s. neutrona em cavalos, e, para exterminar s. neurona em cavalos
US5883095A (en) *	1997-08-07	1999-03-16	University Of Kentucky Research Foundation	Formulations and methods to treat and prevent equine protozoal myeloencephalitis
US5830893A (en) *	1997-04-23	1998-11-03	Mortar & Pestle Veterinary Pharmacy, Inc.	Treatment of equine protozoan myeloencephalitis using triazinediones
EP1032416B1 (de) *	1997-10-20	2007-01-24	Bayer Corporation	Neospora impstoff
US6248329B1 (en)	1998-06-01	2001-06-19	Ramaswamy Chandrashekar	Parasitic helminth cuticlin nucleic acid molecules and uses thereof
MXPA01003542A (es)	1998-10-08	2002-09-18	New Ace Res Company	Composiciones y metodos nuevos para la prevencion y tratamiento de enfermedad causada por protozoarios.
AU2198100A (en) *	1998-12-22	2000-07-12	Bayer Corporation	Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
US6194408B1 (en) *	1998-12-22	2001-02-27	Bayer Corporation	Triazineone compounds for treating diseases due to Sarcocystis, Neospora and Toxoplasma
US6150361A (en) *	1998-12-22	2000-11-21	Bayer Corporation	Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma

1999
- 1999-12-03 DE DE19958388A patent/DE19958388A1/de not_active Withdrawn
2000
- 2000-11-21 JP JP2001541510A patent/JP5031163B2/ja not_active Expired - Lifetime
- 2000-11-21 NZ NZ519327A patent/NZ519327A/en not_active IP Right Cessation
- 2000-11-21 HU HU0203534A patent/HU226379B1/hu unknown
- 2000-11-21 AT AT00977586T patent/ATE298573T1/de active
- 2000-11-21 MX MXPA02005479A patent/MXPA02005479A/es active IP Right Grant
- 2000-11-21 WO PCT/EP2000/011837 patent/WO2001039778A2/de not_active Ceased
- 2000-11-21 EP EP00977586A patent/EP1246624B1/de not_active Expired - Lifetime
- 2000-11-21 CN CN200910142693A patent/CN101632676A/zh active Pending
- 2000-11-21 CA CA2394188A patent/CA2394188C/en not_active Expired - Lifetime
- 2000-11-21 BR BR0015996-4A patent/BR0015996A/pt not_active Application Discontinuation
- 2000-11-21 DE DE50010648T patent/DE50010648D1/de not_active Expired - Lifetime
- 2000-11-21 ES ES00977586T patent/ES2243323T3/es not_active Expired - Lifetime
- 2000-11-21 AU AU15244/01A patent/AU783437B2/en not_active Expired
- 2000-11-21 CN CN00816674A patent/CN1407893A/zh active Pending
- 2000-11-21 DK DK00977586T patent/DK1246624T3/da active
2002
- 2002-05-02 ZA ZA200203476A patent/ZA200203476B/en unknown
2007
- 2007-10-12 US US11/871,302 patent/US9399037B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MXPA02005479A (es)	2003-01-28
ES2243323T3 (es)	2005-12-01
BR0015996A (pt)	2002-08-06
HUP0203534A2 (hu)	2003-01-28
DE50010648D1 (de)	2005-08-04
AU783437B2 (en)	2005-10-27
US20090181040A1 (en)	2009-07-16
HU226379B1 (en)	2008-10-28
NZ519327A (en)	2004-10-29
WO2001039778A3 (de)	2002-01-31
CN1407893A (zh)	2003-04-02
ZA200203476B (en)	2003-05-02
EP1246624B1 (de)	2005-06-29
WO2001039778A2 (de)	2001-06-07
CA2394188A1 (en)	2001-06-07
EP1246624A2 (de)	2002-10-09
JP2003515563A (ja)	2003-05-07
DK1246624T3 (da)	2005-10-03
DE19958388A1 (de)	2001-06-07
ATE298573T1 (de)	2005-07-15
JP5031163B2 (ja)	2012-09-19
HUP0203534A3 (en)	2003-10-28
US9399037B2 (en)	2016-07-26
AU1524401A (en)	2001-06-12
CA2394188C (en)	2010-01-26

Legal Events

Date	Code	Title	Description
2010-01-27	C06	Publication
2010-01-27	PB01	Publication
2010-03-24	C10	Entry into substantive examination
2010-03-24	SE01	Entry into force of request for substantive examination
2010-10-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1140684 Country of ref document: HK
2013-02-27	ASS	Succession or assignment of patent right	Owner name: BAYER INTELLECTUAL PROPERTY GMBH Free format text: FORMER OWNER: BAYER AKTIENGESELLSCHAFT Effective date: 20130123
2013-02-27	C41	Transfer of patent application or patent right or utility model
2013-02-27	TA01	Transfer of patent application right	Effective date of registration: 20130123 Address after: German Monheim Applicant after: Bayer Pharma Aktiengesellschaft Address before: Germany Leverkusen Applicant before: Bayer Aktiengesellschaft
2014-03-19	RJ01	Rejection of invention patent application after publication
2014-03-19	RJ01	Rejection of invention patent application after publication	Application publication date: 20100127
2016-06-17	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1140684 Country of ref document: HK

Publication	Publication Date	Title
Gill et al.	2022	Prospects of halofuginone as an antiprotozoal drug scaffold
Tanaka et al.	2012	Parasiticidal activity of Haemaphysalis longicornis longicin P4 peptide against Toxoplasma gondii
Florin-Christensen et al.	2021	Pursuing effective vaccines against cattle diseases caused by apicomplexan protozoa
de Stefani Munaó Diniz et al.	1999	Clinical problems of sloths (Bradypus sp. and Choloepus sp.) in captivity
US9399037B2 (en)	2016-07-26	Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans
KR20040021678A (ko)	2004-03-10	난포낭을 생산하기 위한 개선된 방법
Sahoo et al.	2021	Vaccination approach to prevent Argulus siamensis infection-success, challenges and preparedness
Behar et al.	2023	Vector-Borne Diseases in Ruminants
Chen et al.	2025	Evaluation of the efficicacy of myrcene in the treatment of Eimeria tenella and Toxoplasma gondii infection
Hinney et al.	2019	Efficacy and safety of ronidazole treatment against Tritrichomonas foetus in a cat colony with multiple disorders
Castro-Hermida et al.	2001	Evaluation of β-cyclodextrin against natural infections of cryptosporidiosis in calves
KR100379026B1 (ko)	2003-04-08	양식 넙치의 스쿠티카충 구제방법
Zaheer et al.	2020	Expiry of a completely splenectomised calf in post-operative period due to mixed piroplasm infection: A case report
Fetterer et al.	2010	Metam sodium reduces viability and infectivity of Eimeria oocysts
AU643483B2 (en)	1993-11-18	Treatment of protozoal diseases
HK1140684A (en)	2010-10-22	Triazinone compounds for treating diseases resulting from infretation with parasitic protozoans
Palermo	2016	Cryptosporidium in fish: Morphological and molecular characterisation
Rufa’i et al.	2022	Evaluation of Antitrypanosomal activity of Tetracycline in animal model
HK1054687A (en)	2003-12-12	Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans
US12520840B2 (en)	2026-01-13	Method for reducing parasite burden in a mosquito
Vreden et al.	1995	Inhibition of Plasmodium berghei liver schizont development and reduction of cytokine production capacity in rats by dietary fish oil supplementation
Kusakisako et al.	2016	Improvement of the cryopreservation method for the Babesia gibsoni parasite by using commercial freezing media
Vasilic	2022	Inside and Out: Exploring Cryptosporidium’s lifecycle with and without a host
Talabi et al.	2012	Clinical observations on three Nigerian Zebu cattle breeds following experimental Trypanosoma congolense infection
CN120459090A (zh)	2025-08-12	化合物ctu-b2r在制备治疗弓形虫病的药物中的应用